表紙
市場調査レポート

膵臓がん:パイプライン製品の分析

Pancreatic Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 200987
出版日 ページ情報 英文 1769 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
膵臓がん:パイプライン製品の分析 Pancreatic Cancer - Pipeline Review, H2 2015
出版日: 2015年12月31日 ページ情報: 英文 1769 Pages
概要

膵臓がんとは、膵臓の組織に悪性細胞(がん細胞)が発生するという疾患で、外分泌系がんとも呼ばれています。主な徴候・症状として、上腹部痛やその背中への拡散、黄疸、食欲不振、体重減少、うつ、血餅などが挙げられます。主な疾病素質には年齢や性別、喫煙、糖尿病、家族歴などがあります。主な治療法には、外科手術、化学療法、放射線治療などが含まれています。

当レポートでは、世界各国での膵臓がん治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

膵臓がんの概要

治療薬の開発

  • 膵臓がん向けパイプライン製品:概要
  • 膵臓がん向けパイプライン製品:比較分析

各企業で開発中の膵臓がん治療薬

大学/研究機関で研究中の膵臓がん治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

膵臓がん治療薬:開発中の製品の一覧(企業別)

膵臓がん治療薬:研究中の製品の一覧(大学/研究機関別)

膵臓がん治療薬の開発に従事している企業(全175社)

膵臓がん:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル(全330件)

  • 各製品の概要、機能メカニズム、研究開発(R&D)の進展状況

膵臓がん治療薬:パイプライン製品の最新動向

膵臓がん治療薬:開発が休止状態の製品

膵臓がん治療薬:開発が中止された製品

膵臓がん関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7415IDB

Summary

Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H2 2015', provides an overview of the Pancreatic Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Pancreatic Cancer Overview
  • Therapeutics Development
  • Pancreatic Cancer - Therapeutics under Development by Companies
  • Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
  • Pancreatic Cancer - Pipeline Products Glance
  • Pancreatic Cancer - Products under Development by Companies
  • Pancreatic Cancer - Products under Investigation by Universities/Institutes
  • Pancreatic Cancer - Companies Involved in Therapeutics Development
  • Pancreatic Cancer - Therapeutics Assessment
  • Drug Profiles
  • Pancreatic Cancer - Recent Pipeline Updates
  • Pancreatic Cancer - Dormant Projects
  • Pancreatic Cancer - Discontinued Products
  • Pancreatic Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Pancreatic Cancer, H2 2015
  • Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Development by Companies, H2 2015 (Contd..9)
  • Number of Products under Development by Companies, H2 2015 (Contd..10)
  • Number of Products under Development by Companies, H2 2015 (Contd..11)
  • Number of Products under Development by Companies, H2 2015 (Contd..12)
  • Number of Products under Development by Companies, H2 2015 (Contd..13)
  • Number of Products under Development by Companies, H2 2015 (Contd..14)
  • Number of Products under Development by Companies, H2 2015 (Contd..15)
  • Number of Products under Development by Companies, H2 2015 (Contd..16)
  • Number of Products under Development by Companies, H2 2015 (Contd..17)
  • Number of Products under Development by Companies, H2 2015 (Contd..18)
  • Number of Products under Development by Companies, H2 2015 (Contd..19)
  • Number of Products under Development by Companies, H2 2015 (Contd..20)
  • Number of Products under Development by Companies, H2 2015 (Contd..21)
  • Number of Products under Development by Companies, H2 2015 (Contd..22)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Development by Companies, H2 2015 (Contd..13)
  • Products under Development by Companies, H2 2015 (Contd..14)
  • Products under Development by Companies, H2 2015 (Contd..15)
  • Products under Development by Companies, H2 2015 (Contd..16)
  • Products under Development by Companies, H2 2015 (Contd..17)
  • Products under Development by Companies, H2 2015 (Contd..18)
  • Products under Development by Companies, H2 2015 (Contd..19)
  • Products under Development by Companies, H2 2015 (Contd..20)
  • Products under Development by Companies, H2 2015 (Contd..21)
  • Products under Development by Companies, H2 2015 (Contd..22)
  • Products under Development by Companies, H2 2015 (Contd..23)
  • Products under Development by Companies, H2 2015 (Contd..24)
  • Products under Development by Companies, H2 2015 (Contd..25)
  • Products under Development by Companies, H2 2015 (Contd..26)
  • Products under Development by Companies, H2 2015 (Contd..27)
  • Products under Development by Companies, H2 2015 (Contd..28)
  • Products under Development by Companies, H2 2015 (Contd..29)
  • Products under Development by Companies, H2 2015 (Contd..30)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Pancreatic Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by 3B Pharmaceuticals GmbH, H2 2015
  • Pancreatic Cancer - Pipeline by 4SC AG, H2 2015
  • Pancreatic Cancer - Pipeline by AB Science SA, H2 2015
  • Pancreatic Cancer - Pipeline by AbbVie Inc., H2 2015
  • Pancreatic Cancer - Pipeline by AbGenomics International, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Ability Pharma, SL, H2 2015
  • Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by ACF Pharmaceuticals, LLC, H2 2015
  • Pancreatic Cancer - Pipeline by Adamed Sp. z o.o., H2 2015
  • Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Advantagene, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Advaxis, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Agenus, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by AGV Discovery, SAS, H2 2015
  • Pancreatic Cancer - Pipeline by AIMM Therapeutics B.V., H2 2015
  • Pancreatic Cancer - Pipeline by Alchemia Limited, H2 2015
  • Pancreatic Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2015
  • Pancreatic Cancer - Pipeline by Almac Discovery Limited, H2 2015
  • Pancreatic Cancer - Pipeline by Altor BioScience Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Ambrx, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Amgen Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015
  • Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by ANP Technologies, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2015
  • Pancreatic Cancer - Pipeline by Apexigen, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Aphios Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2015
  • Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2015
  • Pancreatic Cancer - Pipeline by Aposense Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by Arch Biopartners, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Argon Pharma S.L., H2 2015
  • Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Astellas Pharma Inc., H2 2015
  • Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2015
  • Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2015
  • Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2015
  • Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2015
  • Pancreatic Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015
  • Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
  • Pancreatic Cancer - Pipeline by Bayer AG, H2 2015
  • Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2015
  • Pancreatic Cancer - Pipeline by Beta Pharma, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015
  • Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2015
  • Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2015
  • Pancreatic Cancer - Pipeline by Bioncotech Therapeutics S.L., H2 2015
  • Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2015
  • Pancreatic Cancer - Pipeline by BiOrion Technologies B.V., H2 2015
  • Pancreatic Cancer - Pipeline by Biotest AG, H2 2015
  • Pancreatic Cancer - Pipeline by Biothera, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Biouniversa s.r.l., H2 2015
  • Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Pancreatic Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Cavion LLC, H2 2015
  • Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Cellectis S.A., H2 2015
  • Pancreatic Cancer - Pipeline by Celsion Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Centrose LLC, H2 2015
  • Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2015
  • Pancreatic Cancer - Pipeline by ChemoCentryx, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Chiome Bioscience, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Coare Biotechnology, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Concordia Healthcare Corp., H2 2015
  • Pancreatic Cancer - Pipeline by Confluence Life Sciences, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
  • Pancreatic Cancer - Pipeline by CritiTech, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2015
  • Pancreatic Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015
  • Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by CytoVac A/S, H2 2015
  • Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by CyTuVax B.V., H2 2015
  • Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by e-Therapeutics Plc, H2 2015
  • Pancreatic Cancer - Pipeline by Eisai Co., Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2015
  • Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2015
  • Pancreatic Cancer - Pipeline by Endor Nanotechnologies SL, H2 2015
  • Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2015
  • Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Etubics Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Exelixis, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by FibroGen, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Fujifilm Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Fusion Antibodies Limited, H2 2015
  • Pancreatic Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015
  • Pancreatic Cancer - Pipeline by Genelux Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Genentech, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Genmab A/S, H2 2015
  • Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Pancreatic Cancer - Pipeline by Globeimmune, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by GlycoMimetics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Golden Biotechnology Corp., H2 2015
  • Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by Heat Biologics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by Helix BioPharma Corp., H2 2015
  • Pancreatic Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by iCeutica, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Ignyta, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Immunomedics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Immunotope, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Immunovo BV, H2 2015
  • Pancreatic Cancer - Pipeline by Incuron, LLC, H2 2015
  • Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2015
  • Pancreatic Cancer - Pipeline by Inflection Biosciences Limited, H2 2015
  • Pancreatic Cancer - Pipeline by Innopharmax Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Intica Biomedical, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Inventiva SAS, H2 2015
  • Pancreatic Cancer - Pipeline by Io Therapeutics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Ipsen S.A., H2 2015
  • Pancreatic Cancer - Pipeline by Isarna Therapeutics GmbH, H2 2015
  • Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
  • Pancreatic Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015
  • Pancreatic Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
  • Pancreatic Cancer - Pipeline by Kalos Therapeutics, Inc., H2 2015
  • Pancreatic Cancer - Pipeline by Kancera AB, H2 2015
  • Pancreatic Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015

List of Figures

  • Number of Products under Development for Pancreatic Cancer, H2 2015
  • Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top